Bevacizumab is a monoclonal antibody to vascular endothelial growth factor-A (VEGF). In the pivotal trial in metastatic colorectal cancer (mCRC), addition of bevacizumab to first-line irinotecan, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback